B.Riley keeps Buy rating for Kymera Therapeutics stock

Published on 10/02/2026 at 13:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kymera Therapeutics stock drew a USD 155.00 target from B.Riley on October 1, 2026. Q2 revenue reached USD 65.00 million versus USD 11.50 million.

KYMR, US5015751044, Illustration mit AI erstellt.

Kymera Therapeutics stock received a reiterated Buy rating and a USD 155.00 price target from B.Riley on October 1, 2026, according to Investing.com. The call followed new data on Kymera's oral STAT6 degrader KT-621 in atopic dermatitis.

B.Riley sets USD 155.00 target

B.Riley linked its view to Kymera's BROADEN2 Phase 2b study, which is evaluating KT-621 in a placebo-controlled trial. The study is expected to report results by the end of 2026, while early fourth-quarter data from the KT-579 healthy-volunteer study provide another clinical milestone.

The analyst view carries a clear condition: BROADEN2 must show skin clearance comparable with established treatment while improving itch outcomes and maintaining a lower conjunctivitis rate. That makes the late-2026 data the main test for the valuation behind the USD 155.00 target.

Revenue jumps on partner payments

Kymera reported USD 65.00 million of revenue in the second quarter of 2026, compared with USD 11.50 million in the second quarter of 2025, an increase of 465.22 percent. The company also reported a loss of USD 0.62 per diluted share, narrower than the USD 0.95 loss in the year-ago quarter, according to Yahoo Finance.

All second-quarter revenue came from collaboration agreements. The quarter included a USD 45.00 million option exercise fee tied to Gilead Sciences' license for KT-200 and a USD 20.00 million milestone after Sanofi began a Phase 1 study of KT-485.

Nasdaq value and cash runway

On Nasdaq, KYMR was last at USD 110.12 on October 1, 2026, against a prior close of USD 111.79. Its 52-week range was USD 55.26 to USD 130.05, and its market capitalization was USD 9.1 billion on that date.

Kymera held USD 1.50 billion in cash, cash equivalents and marketable securities as of June 30, 2026, according to Yahoo Finance. Management said that capital supports operations through 2029, giving the company time to advance KT-621 and KT-579 while collaboration payments remain an important revenue source.

Nasdaq quote and investor context

MarketBeat reported that CEO Nello Mainolfi sold 30,000 shares on October 1, 2026, at an average price of USD 113.80. The filing left him with 666,568 shares, while the clinical milestones and cash runway remain the central operating variables for Kymera.